US3

S&P Global Mobility Special Report: US Automotive Market Share Wars will Resume in 2023

Retrieved on: 
Thursday, February 2, 2023
US3, Public expenditure, Ram, Jeep, Lincoln, Original equipment manufacturer, Human, MSRP, Swings, Thought, Sale, Pressure, BEV, Mercedes-Benz, GMC, Inventory, Langley, Research, SUV, Kia, Movement, Forecasting, Hyundai, Mazda, COVID, Head, Ford, ICE, GM, Car dealership, Retail, Automotive industry, Video game, Stellantis, Subaru

SOUTHFIELD, Mich., Feb. 2, 2023 /PRNewswire/ -- After nearly two years of inflated new- and used-car prices – with car dealers asking consumers to pay thousands of dollars over MSRP – the US industry is primed for a reset to previous competitive norms.

Key Points: 
  • A combination of industry factors and macroeconomic conditions could trigger a potentially bloody battle for market share this year, according to an analysis by S&P Global Mobility.
  • "Things will heat up this year when the first tranche of COVID-sold vehicles starts returning to market," predicts Dave Mondragon, vice president of product development for S&P Global Mobility.
  • Among luxury brands, Mercedes-Benz and Lincoln still showed the most remaining 2022 vehicles in dealer advertised inventory, according to the S&P Global Mobility analysis.
  • From a forecasting perspective, S&P Global Mobility recently downgraded the US demand settings for 2023 due to darkening economic clouds.

Elix’s Cycle Balance Is Found Clinically Effective for 15 Different Symptoms

Retrieved on: 
Thursday, November 17, 2022
Research, Clinical Trials, Other Health, Alternative Medicine, Health, Pharmaceutical, General Health, Other Science, Science, Well, Clinical trial, Migraine, OTC, Health, FAQ, Elix, IRB, TCM, Shadow, US3, Health care, Research, Woman, Cramp, Shame, Pain, Menstruation, Stigma, Traditional Chinese medicine, Knowledge, Birth control, Dietary supplement, Wisdom

In Q1 2022, Elix completed its first Institutional Review Board (IRB)-approved independent clinical trial to formally evaluate if Cycle Balance formulas provided relief from menstrual symptoms and resulted in a reduced need for OTC pain medication.

Key Points: 
  • In Q1 2022, Elix completed its first Institutional Review Board (IRB)-approved independent clinical trial to formally evaluate if Cycle Balance formulas provided relief from menstrual symptoms and resulted in a reduced need for OTC pain medication.
  • The trial took place over three months and consisted of 65 participants between the ages of 18-36.
  • Participants were provided with their own tailored blend of Cycle Balance, were instructed on how to take it, and completed monthly surveys before, during, and after the three month trial period to track changes in their symptoms.
  • We at Elix are thrilled that the trial demonstrates how Cycle Balance herbal medicine supports menstrual symptoms holistically.

85% of US ER Doctors Report Increase in RSV cases in Past Two Weeks, Says Wave 1 of InCrowd RSV Tracking Report

Retrieved on: 
Wednesday, November 2, 2022
Other Health, Managed Care, Professional Services, Pharmaceutical, Infectious Diseases, Hospitals, Other Professional Services, Biotechnology, Nursing, Practice Management, Consulting, Health, Awareness, Respiratory syncytial virus, Life, CEO, Pneumonia, Acquisition, Research, Time, Hospital, RSV, Physician, Bronchiolitis, Human, US3, Frazier Healthcare Partners, Critical care, Patient, Caregiver, Pharmaceutical industry

Nearly half (45%) of all survey respondents state that their patients have more severe cases than years past, with 6% of these characterizing cases as much more severe.

Key Points: 
  • Nearly half (45%) of all survey respondents state that their patients have more severe cases than years past, with 6% of these characterizing cases as much more severe.
  • Data are from a real-time tracking report on RSV released by InCrowd , a global pioneer of real-time, automated insights for the life science industry and an Apollo Intelligence (Apollo) brand.
  • Well be tracking the voice of emergency physicians every two weeks as an important barometer for US critical care resources.
  • Among the 85% of physicians in InCrowds report who note an increase in cases over the previous two weeks, 30% characterize the rise as a strong increase.

Ninja Continues Kitchenware Disruption with Launch of Ninja™ Foodi™ NeverStick™ Bakeware

Retrieved on: 
Thursday, October 6, 2022
Kohl's, US1, Multimedia, Collection, Browning, SVP, Company, Teenage Mutant Ninja Turtles food tie-ins, Food, Amazon, Cooking, US3, View, Soda–lime glass, Baking, Ninja

NEEDHAM, Mass., Oct. 6, 2022 /PRNewswire/ -- Ninja, the top-growing cookware brand in the US1, is expanding its presence with its first-ever bakeware collection, the Ninja™ Foodi™ NeverStick™ Bakeware. Easy-to-use, versatile and made with Ninja's commitment to quality, the new bakeware joins existing cookware and cutlery products to round out a complete kitchenware collection. Ninja's NeverStick™ Bakeware easily releases food and wipes clean, giving consumers even more confidence in the kitchen than before.

Key Points: 
  • Ninja's NeverStick Bakeware easily releases food and wipes clean,giving consumers even more confidence in the kitchen than before.
  • "At Ninja, we believe a kitchen that never stops deserves tools that never compromise," said Jonathan Webster, SVP, Ninja Global Marketing.
  • The Ninja Foodi NeverStick Bakeware joins Ninja's existing line of kitchenware products, including:
    The Ninja Foodi NeverStick Cookware , which is the #1 Cookware Set in the US3, and the Ninja Foodi NeverStick Premium Set PossiblePan .
  • Purchase the Ninja Foodi NeverStick 5-Piece Bakeware Set for $99.99 on NinjaKitchen.com and other major retailers including Amazon and Kohl's .

Aurion Biotech Nominated for Prix Galien Startup Award

Retrieved on: 
Thursday, August 18, 2022
Health, Other Science, Clinical Trials, Research, Science, Optical, Biotechnology, Endothelium, Hoffmann-La Roche, CEO, Corneal transplantation, Wyeth, Nobel Prize, Visual acuity, Research, Patient, Biotechnology, Company, US3, Cell, Paganini Competition, Ophthalmology, Toyota Aurion, Endothelial dysfunction, Digital health, Health, Former, Pharmaceutical industry, Medical imaging, Dentistry, Incubator

Aurion Biotech , whose mission is to restore vision to millions of patients with its life-changing regenerative therapies, today announced it has been nominated for the prestigious Prix Galien Startup Award.

Key Points: 
  • Aurion Biotech , whose mission is to restore vision to millions of patients with its life-changing regenerative therapies, today announced it has been nominated for the prestigious Prix Galien Startup Award.
  • We are delighted and honored to be participating in this prestigious award process, said Greg Kunst, Aurion Biotech chief executive officer.
  • The Prix Galien was created in 1970 by Roland Mehl in honor of Galien, the father of medical science and modern pharmacology.
  • The Aurion Biotech team is preparing for clinical trials in the U.S. To learn more about Aurion Biotech, visit www.aurionbiotech.com
    2 JAMA: Global Survey of Corneal Transplantation & Eye Banking: https://jamanetwork.com/journals/jamaophthalmology/fullarticle/2474372

Tinley’s Closes $1.865 Million Non-Brokered Private Placement; Richard Gillis Acquires 1 Million Units

Retrieved on: 
Friday, October 15, 2021
Diamond, Leadership, Multilateral, Goal, Coca-Cola Enterprises, Indian stock exchange, CPG, General manager, Terminology, LOS, CSE, Growth, OTC, Diamond Estates Wines & Spirits Ltd., Engineering, Marketing, US3, Southwestern United States, Crystal Head Vodka, News, SEDAR, GLOBE, Phrase, Company, Coca-Cola, Forward-looking statement, Black Velvet, Unit, Diageo, Energy drink, Offering, Advisory board, Public expenditure, CEO, Twitter, Minority, MI, Security (finance), Renewable energy, Coffee

Of the Units sold as part of the Offering, Richard Gillis, recently appointed to the role of President and Chief Operating Officer of Tinleys USA, subscribed for 1 million Units.

Key Points: 
  • Of the Units sold as part of the Offering, Richard Gillis, recently appointed to the role of President and Chief Operating Officer of Tinleys USA, subscribed for 1 million Units.
  • Prior to joining Tinley, Mr. Gillis served as President of Youngs Market Company which, under his leadership, generated US3$ billion annually in sales.
  • I made this investment to demonstrate my confidence in Tinleys growth trajectory, said Richard Gillis.
  • Mr. Stodart has returned to active advisory work for Tinleys with a focus on driving the Companys expansion in Canada.